Summary
There are a number of cardiovascular conditions in which calcium channel antagonists (CCAs) are accepted as first-line therapy, including Prinzmetal's angina and Raynaud's phenomenon. The real issue is whether symptomatic relief of angina or effective reduction of blood pressure (BP) is matched by a good safety record. In effort angina, verapamil is as safe as metoprolol, and nifedipine (tablet form) is as safe as atenolol. In unstable angina, intravenous diltiazem is better than intravenous nitroglycerin; there are no similar data on beta-blockade. Short-acting nifedipine is contraindicated in unstable angina. There is no place for CCAs in acute phase myocardial infarction and short-acting nifedipine is contraindicated. In the post-MI phase, two specific groups of patients benefit from diltiazem or verapamil: (1) those who had non-Q-wave infarcts and (2) those who are hypertensive. The DAVIT studies argue for the safety and efficacy of verapamil but do not allow comparisons with standard beta-blocker therapy. In the treatment of hypertension, the recommendation often made that a low-dose diuretic should be first-line therapy holds for the elderly with systolic hypertension but is not based on prospective studies in the case of younger patients. High-dose diuretics may have adverse effects, as reported in two case-controlled studies. Prospective outcome data favoring beta-blocker monotherapy as first-line therapy are limited, especially in the elderly, while case-control studies suggest an increased incidence of cardiac death in those treated by beta-blockers. CCAs may be the preferred first-line antihypertensive treatment for those groups in whom low-dose diuretics are unlikely to work as monotherapy.
Similar content being viewed by others
References
Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326–1331.
Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620–625.
Pahor M, Guralnik JM, Corti M, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43: 1191–1197.
Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068–1073.
Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995;26:914–919.
Pepine CJ, Cohn PF, Prakash C, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. The Atenolol Silent Ischemia Study (ASIST). Circulation 1994;90:762–768.
Rehnqvist N, Hjemdahl P, Billing E, et al. Effects of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study In Stockholm (APSIS). Eur Heart J 1996;17:76–81.
Dargie HJJ, for the TIBET Study Group. Medical treatment of angina can favourably affect outcome. Eur Heart J 1993;14(Abstract Suppl):304.
Opie LH. Calcium channel antagonists in the management of anginal syndromes: Changing concepts in relation to the role of coronary vasospasm. Prog Cardiovasc Dis 1996;38: 291–314.
Göbel EJAM, Hautvast RWM, vanGilst WH, et al. Randomised, double-blind trial of intravenous diltiazem versus glyceryl trinitrate for unstable angina pectoris. Lancet 1995;346:1653–1657.
Ferguson JJ, Momomura S. Highlights from the 58th Annual Scientific Meeting of the Japanese Circulation Society. Circulation 1994;90:2194–2196.
Theusen L, Jorgenson JR, Kvistgaard HJ. Effect of verapamil on enzyme release after early intravenous administration in acute myocardial infarction: A double-blind randomized trial. Br Med J 1983;286:1107–1108.
Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction. Br J Clin Pharmacol 1986;21:197S-204S.
Goldbourt U, Behar S, Reicher-Reiss H, et al. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153: 345–353.
Sirnes PA, Overskeid K, Pedersen TR, Bathen J, et al. Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: The Norwegian Nifedipine Multicenter Trial. Circulation 1984;70:638–644.
Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: Implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992;19:1622–1623.
Fischer Hansen J, The Danish Study Group on verapamil in myocardial infarction. Treatment with verapamil during and after an acute myocardial infarction: A review based on the Danish verapamil infarction trials I and II. J Cardiovasc Pharmacol 1991;18(Suppl 6):S20-S25.
Fischer Hansen J. Verapamil prevents sudden death in patients with increased heart size after an acute myocardial infarction. Cardiovasc Drugs Ther 1993;7:381–382.
Messerli F, WE Boden, Fischer-Hansen J, Schechtman KB. Heart rate lowering calcium antagonists (HRL-CA) in hypertensive post MI patients. J Am Coll Cardiol 1996;27: 178A.
Boden WE, Fisher-Hansen J, Lau J, Roberts R. Beneficial effect of heart rate-lowering calcium channel blockers (diltiazem, verapamil) on reducing long-term (12–18 month) cardiac death and nonfatal reinfarction in patients recovering from acute non-Q-wave myocardial infarction (abstr). Circulation 1995;92(Suppl):1–81.
Lichstein E, Hager D, Gregory JJ, Fleiss JL, Rolnitzky LM, Bigger JT. Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. J Am Coll Cardiol 1990;16:1327–1332.
Poole-Wilson PA. DEFIANT II: The effect of nisoldipine vs. placebo on ventricular function and exercise capacity. Presented at the 17th Congress of European Society of Cardiology, Amsterdam, The Netherlands, 1995.
Packer M. The PRAISE trial (Prospective Randomized Amlodipine Survival Evaluation): Background and main results. Presented at the American College of Cardiology Annual Meeting, 1995.
Cohn JN. V-HEFT-III: Efficacy and outcome with felodipine in heart failure. Presented at the 17th-Congress of the European Society of Cardiology, Amsterdam, The Netherlands, 1995.
Gong L, Zwang W, Zhu Y. STONE (Shanghai Trial Of Nifedipine in the Elderly) Study. Abstract presented to the Seventh European Meeting on Hypertension, 1995.
MRC Medical Research Council Working Party. MRC trial of treatment of mild hypertension: Principal results. Br Med J 1985;291:97–104.
MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: Principal results. Br Med J 1992;304:405–412.
Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852–1857.
Hoes AW, Grobbee DE, Lubsen J, Man in 't Veld AJ, van derDoes E, Hofman A. Diuretics, β-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995;123:481–487.
Cooperative Research Group. Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:24: 3255–3264.
Ekbom R, Dahlöf B, Hansson L, et al. Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: A report from the STOP-Hypertension study. J Hypertens 1992;10:1525–1530.
Warram JH, Laffel LMB, Valsania P, Christlieb AR, Krolewski AS. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991;151:1350–1356.
Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six anti-hypertensive agents with placebo. N Engl J Med 1993;328: 914–921.
Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993;270: 713–724.
Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995;26:143–149.
Arstall MA, Beltrame JF, Mohan P, Wuttke RD, Esterman AJ, Horowitz JD. Incidence and adverse effects during treatment with verapamil for suspected acute myocardial infarction. Am J Cardiol 1992;70:1611–1612.
Pahor M, Guralnik JM, Furberg C, Carbonin P, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996;347:1061–1065.
Author information
Authors and Affiliations
Additional information
This manuscript was handled by the San Francisco Office of this journal with the aid of two anonymous referees.
Rights and permissions
About this article
Cite this article
Opie, L.H. Calcium channel antagonists should be among the first-line drugs in the management of cardiovascular disease. Cardiovasc Drug Ther 10, 455–461 (1996). https://doi.org/10.1007/BF00051110
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00051110